Biotech entity
Cathie Wood is most often covered alongside ARK Invest, which appears in 1 of these 2 stories. They are less corroborated than the beat average, carrying 2.5 original sources each against 4.3 for the same window. The clearest coverage concentration is funding: 1 of 2 stories, with the rest divided among 1 other category.
Last mentioned: Jul 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Cathie Wood is most often covered alongside ARK Invest, which appears in 1 of these 2 stories. They are less corroborated than the beat average, carrying 2.5 original sources each against 4.3 for the same window. The clearest coverage concentration is funding: 1 of 2 stories, with the rest divided among 1 other category. Their average consequence score of 5 runs below the beat's 5.9 for that window. This profile follows 2 Biotech stories mentioning Cathie Wood across the period from March 11, 2026 to March 16, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 71 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Cathie Wood. Shared-story counts are live from our verified record — not editorial picks.
Cathie Wood's ARK Investment Management has purchased $2 million worth of Tempus AI shares, reinforcing its position in the precision medicine firm despite a 15% year-to-date decline. The move underscores Wood's commitment to 'coiled spring' AI and biotech assets, even as her flagship funds face significant performance headwinds compared to the broader market.
Source: Kansascity · Miamiherald
ARK Invest, led by Cathie Wood, has significantly increased its position in CRISPR Therapeutics (CRSP), signaling continued high conviction in the gene-editing pioneer despite recent market fluctuations. This move highlights Wood's strategy of doubling down on disruptive genomic technologies during periods of valuation compression.
Source: seekingalpha.com · Seeking Alpha
Cathie Wood is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
